Frazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion ...

MelliCell CEO Ben Pope, Ph.D., echoed the need for increased access to funds. The Greater Boston-based biotech company has a ...

The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from ...

Andy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June. Plump joined the Japanese drugmaker in 2015, arriving from Sanofi to initially serve as ...

Clinical research company nPhase has launched an end-to-end clinical data management platform designed to help trial sponsors ...

Neuro-focused Encoded Therapeutics has bagged a $275 million series F round to support its Dravet syndrome asset and scale up ...

Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladd | Tyra Biosciences has reported initial phase 2 ...

Evommune’s G-protein coupled receptor X2 (MRGPRX2) antagonist has flunked another phase 2 trial, wiping out the biotech’s ...

A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the ...

Luma Group today announced the final close of its inaugural life sciences venture capital fund, totaling $410 million. | Luma Group announced the final close of its inaugural life sciences venture ...

Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival (PFS) demonstrated by its OX40 agonist ...

Novo Nordisk has given up on two more phase 3 trials of ziltivekimab, further eroding the prospects for a molecule that ...